Synonyms: 341, PS; bortezomib; 179324-69-7; Q425; SC-23571; SMR003500787; AB0017579; AB2000734; AX8106087; RT-000308; ST2406732; FT-0082488; FT-0602235; Velcade; SW208077-3; KS-00000761; D03150; Q-4365; AB01273951-01; AB01273951-02; AB01273951_03; 324B697; SR-01000939863; I14-3268; PS-341; SR-01000939863-2; BRD-K88510285-001-02-0; Velcade, MG-341, PS-341,179324-69-7; (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-6-carboxamido)propanamido)butylboronic acid; (1R)-3-Methyl-1-({(2S)-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propanoyl}amino)butylboronic acid, AldrichCPR; (R)-3-METHYL-1-((S)-3-PHENYL-2-(PYRAZINE-2-CARBOXAMIDO)PROPANAMIDO)BUTAN-2-YLBORONIC ACID; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]-butyl]boronic acid; [(1R)-3-METHYL-1-[[(2S)-1-OXO-3-PHENYL-2-[(PYRAZINYLCARBONYL)AMINO]PROPYL]AMINO]BUTYL]-BORONIC ACID; Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (PS-341); radiciol; Peptide boronate; Velcade(PS-341); (1S,2R) Bortezomib; Bortezomib [USAN:INN]; Boronic acid, L-(S)-; D0SH3I; Bortezomib(JAN/USAN/INN); LDP341; Peptidyl boronic acid derivative; LDP-341; Bortezomib (Proteasome inhibitor); Dipeptidyl boronic acid derivative; PS341; Bortezomib, 98% - 25MG 25mg; C19-H25-B-N4-O4; CID387447; 341, PS; ACN-030054; CS-O-00482; CS-O-20087; Ps 341; Velcade, MG-341, PS-341, Bortezomib; A2614; A10160; C400082; D000069286; n-(2-pyrazine)carbonyl-l-phenylalanine-l-leucine boronic acid; BO2; DPBA; UNII-69G8BD63PP; Bortezomib (Velcade); N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; LDP 341; MLN-341; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; 69G8BD63PP; CHEMBL325041; Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-; CHEBI:52717; MFCD09056737; MG-341; NSC681239; LDP-341; ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid; NSC-681239; LDP 341; NCGC00242506-02; S1013; PS 341 (pharmaceutical); DSSTox_CID_20980; DSSTox_RID_79609; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; DSSTox_GSID_40980; LDP341; MG 341; Pyz-Phe-boroLeu; NSC 681239; (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid; [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid; Velcade (TN); CAS-179324-69-7; Brotezamide; PROSCRIPT BORONIC ACID; Bortezomib [USAN:INN:BAN]; PS 341; C19H25BN4O4; HSDB 7666; Bortezomib,Velcade; LPD 341; LPD-341; Velcade, Radiciol; NCGC00168751-01; NCGC00181022-01; Velcade (Millenium); PubChem17777; PS-341; 3mg0; AC1L8TUW; cc-75; MLS004774142; Bortezomib (JAN/USAN/INN); SCHEMBL192129; GTPL6391; DTXSID3040980; CTK8B8979; AOB6368; PS341; GXJABQQUPOEUTA-RDJZCZTQSA-N; ((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid; Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-; Boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (S-(R*,S*))-; N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide; N-((1S)-1-benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide; Tox21_112630; Tox21_112672; ABP000234; ANW-61718; Velcade; BDBM50069989; CB0261; AKOS015909706; Tox21_112672_1; ZINC169746649; AM81235; API0001750; CS-1039; DB00188; MG-341; PS-341; Bortezomib; PB14673; RL02288; Bortezomib (Velcade MG-341 PS-341); Bortezomib/Velcade, MG-341, PS-341; NCGC00242506-01; NCGC00242506-07; AS-15721; BC201423; HY-10227; NCI60_029010;